Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) started the day on Wednesday, with a price increase of 5.11% at $40.29, before settling in for the price of $38.33 at the close. Taking a more long-term approach, RARE posted a 52-week range of $37.02-$60.37.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 48.58% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 2.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.40%. This publicly-traded company’s shares outstanding now amounts to $92.41 million, simultaneously with a float of $86.25 million. The organization now has a market capitalization sitting at $3.73 billion. At the time of writing, stock’s 50-day Moving Average stood at $42.40, while the 200-day Moving Average is $47.19.
Ultragenyx Pharmaceutical Inc (RARE) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Ultragenyx Pharmaceutical Inc’s current insider ownership accounts for 6.76%, in contrast to 95.14% institutional ownership. According to the most recent insider trade that took place on Mar 06 ’25, this organization’s Chief Financial Officer sold 1,785 shares at the rate of 40.40, making the entire transaction reach 72,114 in total value, affecting insider ownership by 106,169. Preceding that transaction, on Mar 03 ’25, Company’s CBO & EVP sold 6,028 for 42.10, making the whole transaction’s value amount to 253,779. This particular insider is now the holder of 265,238 in total.
Ultragenyx Pharmaceutical Inc (RARE) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.38 per share during the current fiscal year.
Ultragenyx Pharmaceutical Inc’s EPS increase for this current 12-month fiscal period is 16.40% and is forecasted to reach -3.64 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 69.25% through the next 5 years, which can be compared against the 2.45% growth it accomplished over the previous five years trading on the market.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Let’s observe the current performance indicators for Ultragenyx Pharmaceutical Inc (RARE). It’s Quick Ratio in the last reported quarter now stands at 2.24. The Stock has managed to achieve an average true range (ATR) of 1.77. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.65.
In the same vein, RARE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.34, a figure that is expected to reach -1.56 in the next quarter, and analysts are predicting that it will be -3.64 at the market close of one year from today.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
If we take a close look at the recent performances of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), its last 5-days Average volume was 0.86 million that shows plunge from its year to date volume of 0.87 million. During the previous 9 days, stock’s Stochastic %D was recorded 25.81% While, its Average True Range was 1.75.
Raw Stochastic average of Ultragenyx Pharmaceutical Inc (RARE) in the period of the previous 100 days is set at 15.27%, which indicates a major fall in contrast to 40.38% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 42.71% that was higher than 37.36% volatility it exhibited in the past 100-days period.
